Diana Pelov

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

Jacqueline A. French, John A. Lawson, Hiroko Ikeda et al. · The Lancet · 2016 · 747 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial

Paolo Curatolo, David Neal Franz, John A. Lawson et al. · The Lancet Child & Adolescent Health · 2018 · 116 citations

Medicine, Neurology, Pediatrics +13

Everolimus for treatment-refractory seizures in TSC

David Neal Franz, John A. Lawson, Hiroko Ikeda et al. · Neurology Clinical Practice · 2018 · 107 citations · Full text

Medicine, Neurology, Pharmacotherapy +14

RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma

Alain Ravaud, Carlos H. Barrios, B. Yа. Alekseev et al. · Annals of Oncology · 2015 · 79 citations

Medicine, Oncology, Pharmacotherapy +14

Phase 1 Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML.

Francis G. Giles, Charles A. Schiffer, Hagop M. Kantarjian et al. · Blood · 2004 · 71 citations

Medicine, Oncology, Pharmacology +13